[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100636765":3},{"organization":4,"armGroups":7,"interventions":29,"overallOfficials":33,"centralContacts":40,"locations":46,"responsibleParty":64,"collaborators":33,"id":66,"slug":33,"hasResults":67,"nctId":68,"briefTitle":69,"officialTitle":69,"acronym":70,"eligibilityCriteria":71,"healthyVolunteers":67,"sex":72,"minAge":73,"maxAge":74,"enrollmentInfo":75,"targetDuration":33,"studyType":78,"phases":79,"briefSummary":81,"conditions":82,"keywords":33,"overallStatus":85,"whyStopped":33,"lastUpdateSubmitDate":86,"lastUpdatePostDateStruct":87,"startDateStruct":90,"completionDateStruct":92,"leadSponsor":94,"locationsCount":95},{"fullName":5,"class":6},"University Hospital, Clermont-Ferrand","OTHER",[8,14,19,24],{"label":9,"type":10,"description":11,"interventionNames":12},"HMG","EXPERIMENTAL","Patients included in the \"HMG\" arm will receive the medical device of the same name.",[13],"Device: HMG",{"label":15,"type":10,"description":16,"interventionNames":17},"PHN","Patients included in the \"PHN\" arm will receive the medical device of the same name.",[18],"Device: PHN",{"label":20,"type":10,"description":21,"interventionNames":22},"PHR","Patients included in the \"PHR\" arm will receive the medical device of the same name.",[23],"Device: PHR",{"label":25,"type":10,"description":26,"interventionNames":27},"TUR","Patients included in the \"TUR\" arm will receive the medical device of the same name.",[28],"Device: TUR",[30,34,36,38],{"type":31,"name":9,"description":11,"armGroupLabels":32,"otherNames":33},"DEVICE",[9],null,{"type":31,"name":15,"description":16,"armGroupLabels":35,"otherNames":33},[15],{"type":31,"name":20,"description":21,"armGroupLabels":37,"otherNames":33},[20],{"type":31,"name":25,"description":26,"armGroupLabels":39,"otherNames":33},[25],[41],{"name":42,"role":43,"phone":44,"phoneExt":33,"email":45},"Lise Laclautre","CONTACT","+33473754963","promo_interne_drci@chu-clermontferrand.fr",[47],{"facility":48,"status":33,"city":49,"state":33,"zip":50,"country":51,"countryCode":52,"cosmosGeoPoint":53,"geoPoint":58,"contacts":59},"Chu Clermont Ferrand","Clermont-Ferrand","63003","France","FR",{"type":54,"coordinates":55},"Point",[56,57],3.08682,45.77969,{"lat":57,"lon":56},[60,61],{"name":42,"role":43,"phone":33,"phoneExt":33,"email":45},{"name":62,"role":63,"phone":33,"phoneExt":33,"email":33},"Gisèle PICKERING","PRINCIPAL_INVESTIGATOR",{"type":65,"investigatorFullName":33,"investigatorTitle":33,"investigatorAffiliation":33,"oldNameTitle":33,"oldOrganization":33},"SPONSOR","100636765",false,"NCT07569939","Evaluation of Treatments for Sore Throat Associated With Acute Pharyngitis and\u002For Viral Tonsillitis","PharyTol","Inclusion Criteria:\n\n* Pharyngitis or tonsillitis or acute nasopharyngitis or viral-origin sore throat with odynophagia that began less than 72 hours before the inclusion visit according to the investigator's judgment\n* Bacterial rhinopharyngitis with negative TROD test\n* Effective contraception for female patients of childbearing age\n* Cooperation and sufficient understanding to comply with the requirements of the trial\n* Acceptance of registration in the SI-RIPH database\n* Having received informed information and agreeing to give written consent\n* Affiliated with the French Social Security scheme.\n\nExclusion Criteria:\n\n* Hypersensitivity\u002Fprevious allergy to any of the product components,\n* Pharyngitis or tonsillitis or acute rhinopharyngitis complicated (phlegmon, acute otitis media, pneumonia…) or severely intolerable cough,\n* Positive antigen test for influenza A\u002FB or COVID-19 and infection requiring etiological treatment according to the recommendations,\n* Other ongoing treatments for acute pharyngitis or tonsillitis (local treatment, antibiotics, corticosteroids, antiretroviral…),\n* Comorbidities or health conditions deemed incompatible with the trial by the investigator,\n* Recent otorhinolaryngology surgery (\\\u003C6 months),\n* Pulmonary pathology (Chronic Obstructive Pulmonary Disease, asthma…),\n* Immunosuppression (according to patient's report),\n* Pregnant or breastfeeding women,\n* Currently participating in another clinical trial, or in the exclusion period, or having received total compensation of more than €6,000 in the 12 months prior to the start of the trial,\n* Benefiting from legal protection measures (guardianship, trusteeship, deprivation of liberty, judicial protection).","ALL","18 Years","70 Years",{"count":76,"type":77},160,"ESTIMATED","INTERVENTIONAL",[80],"NA","The objective of this study is to conduct post-marketing clinical follow-up of four products: HMG, PHN, PHR, and TUR. This follow-up will consist of collecting clinical data in real-life conditions to confirm the tolerance, safety, and efficacy of medical devices used in the treatment of sore throats related to acute pharyngitis and\u002For viral-origin tonsillitis, while also assessing the benefit\u002Frisk ratio of the products.",[83,84],"Acute Pharyngitis","Viral Sore Throat","NOT_YET_RECRUITING","2026-05-06",{"date":88,"type":89},"2026-05-11","ACTUAL",{"date":91,"type":77},"2026-05",{"date":93,"type":77},"2028-01",{"name":5,"class":6},1]